title: Network Meta-analysis of Treatments for Chronic Plaque Psoriasis in Canada.
abstract: BACKGROUND
  Psoriasis affects approximately 500,000 Canadians. Eight treatments are currently licensed for chronic plaque psoriasis in Canada.
  
  
  OBJECTIVE
  To compare the efficacy of systemic treatments for chronic plaque psoriasis for the outcome > 75% reduction in the Psoriasis Area and Severity Index (PASI) using network meta-analysis.
  
  
  METHODS
  PubMed and clinicaltrials.gov databases were searched up until October 15, 2013, for phase III clinical trials. A consistency model based on a random-effects bayesian statistical framework was used to compare the rates of > 75% PASI reduction across trials.
  
  
  RESULTS
  Twenty-one studies were included in the network analysis. Infliximab had significantly greater odds of producing > 75% reduction in the PASI compared to all treatments. All treatments conferred greater odds of > 75% PASI reduction compared to placebo.
  
  
  CONCLUSIONS
  Although infliximab had the highest efficacy relative to other systemic treatments for psoriasis, adverse effects, cost, and patient preferences should also be considered when deciding on treatment.
authors.forename: Aditya K
authors.initials: AK
authors.lastname: Gupta
authors.forename: Deanne
authors.initials: D
authors.lastname: Daigle
authors.forename: Danika C A
authors.initials: DC
authors.lastname: Lyons
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D000077944:Alefacept; D002170:Canada; D017326:Clinical Trials, Phase III as Topic; D003879:Dermatologic Agents / Q000627:therapeutic use*; D000068800:Etanercept / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012720:Severity of Illness Index; D000069549:Ustekinumab / Q000627:therapeutic use
chemical_list: D003879:Dermatologic Agents; D011993:Recombinant Fusion Proteins; D000069285:Infliximab; D000077944:Alefacept; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept; D008727:Methotrexate